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1. Introduction 
1.1 The origin, evolution and distribution of HIV: Introduction of HIV into the human 
population 
There are several lines of evidence, which suggest that HIV-1 and HIV-2 originated from 
primates and were introduced into the human population via cross-species transmission 
events (Sharp et al., 1995). The viral genome structure of the simian form of the virus, 
simian immunodeficiency virus (SIV) is very similar to that of HIV (Huet et al., 1990), and 
phylogenetic relatedness has been established (Gao et al., 1999; Hirsch et al., 1989). SIV 
has been shown to infect primates that live in geographical areas where HIV is endemic 
(Gao et al., 1999; Hirsch et al., 1989), and possible routes of transmission, such as the 
butchering of primates for food and keeping monkeys as pets, have been proposed (Gao 
et al., 1999). 
A natural primate host for HIV-1 has been proposed however there still remains some 
controversy. Strains of SIV (SIVcpz) from the chimpanzee Pan troglodytes troglodytes, 
phylogenetically cluster closer to HIV-1 strains than many other characterized SIV strains 
(Gao et al., 1999). However there is still a moderate amount of diversity between SIVcpz and 
HIV-1, and the prevalence of SIV infections in wild chimpanzees is low. There are three 
major groups within HIV-1, M (main), O (outlier) and N (new, or ‘non-O non-M’). Each of 
the three groups of HIV-1 share a common branch with SIVcpz strains, but do not diverge 
from a common stem with SIVcpz, suggesting that they each arose from different cross-
species transmissions (Gao et al., 1999; Thomson et al., 2002b). To support the idea that P.t. 
troglodytes is the natural reservoir of HIV, the HIV-1 N group was shown to be a 
recombinant between diverse viral strains within the HIV/SIVcpz group, suggesting an 
ancestral recombination in this sub-species of chimpanzee (Gao et al., 1999; Garcia et al., 
1999). 
It is thought that the HIV-1 M group originated in the Democratic Republic of Congo, as an 
extremely high genetic diversity is seen within the region (Vidal et al., 2000) and the earliest 
confirmed HIV-1 infection was found there in a stored serum sample from 1959 (Zhu et al., 
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1998). Based on sequence analysis of the HIV-1 M group, it was estimated that these strains 
arose from a common ancestor in about 1931 (Korber et al., 2000). 
Unlike HIV-1, the origin of HIV-2 is more definitive. The discovery of a form of SIV in sooty 
mangabeys (SIVsm) which is nearly identical to HIV-2, and which is found in these primates 
from the area where HIV-2 circulates in humans, provides very strong evidence that HIV-2 
came from these primates (Gao et al., 1992). At present, there are eight designated groups of 
HIV-2, A-H, which are analogous to the HIV-1 groups (M, N and O) although, groups C-H 
have only been identified in single individuals (Chen et al., 1997; Damond et al., 2004). All 
groups of HIV-2 are believed to have arisen from individual cross-species transmission 
events from sooty mangabeys (Chen et al., 1996). Analysis conducted with HIV-2 strains 
from subtypes A and B, dated a recent common ancestor to around 1940 and 1945 
respectively (Lemey et al., 2003). 
Currently, there are 33 million people living with HIV/AIDS globally with 16,000 new 
infections happening every day (UNAIDS 2010) (Figure 1). As the acquired immune 
deficiency syndrome (AIDS) pandemic enters its third decade, the number of people living 
with human immunodeficiency virus (HIV) infection continues to increase. Although the 
HIV/AIDS epidemic was recognized in Southeast Asia later than elsewhere, local risk 
behaviors have allowed the epidemic to expand rapidly. Today, injecting drug use (IDU) 
accounts for up to 70% of HIV-1 transmission in many Asian countries, including China, 
Indonesia, Malaysia, Myanmar, Eastern India and Vietnam (Saksena et al., 2005). Also, there 
is ample evidence that heterosexual transmission through commercial sex workers has 
increased over the last few years (Saksena et al., 2005). 
 
 
 
 
 
Fig. 1. Estimation of global adult prevalence in 2007, with an approximately 33 million of 
people living with HIV. Diagram source: UNAIDS, 2008: Report on the global AIDS 
epidemic. 
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Fig. 2. Map showing the global dispersal of diverse HIV subtypes (represented by single 
letter codes) and their replacement by circulating recombinant forms (CRFs). 
2. Genetic diversity in HIV: Recombination – A unique trait for the 
continuation of viral progeny 
One of the major hallmarks of HIV infection is high genetic diversity. This high genetic 
diversity in HIV-1 is attributed to the infidelity of its reverse transcriptase enzyme, which 
leads to high rates of mutation [Preston et al., 1988] and rapid viral variant turnover in 
patients-termed quasispecies [Ho et al., 1995 and Wei et al., 1995]. This quasispecies or the 
swarm of viral variants is a powerful asset of HIV in creating recombinants with superior 
ability to survive, evade and infect in vivo. In addition, the subtypic diversity within HIV-1 M 
group also provides the virus with a wider selection of strains to recombine with and disperse 
effectively by creating creating virulent forms. Currently, major subtypes are being replaced 
by circulating recombinant forms (CRFs), the evidence of which can be seen in figure 2. 
The HIV-1 M group can be divided into 9 subtypes (A-D, F-H, J and K), and some subtypes are 
further broken down into subsubtypes, according to their topologies within phylogenetic 
trees. There is possibly a 10th subtype, L, for which 2 full-length sequences have been 
identified (Mokili et al., 2002). All of these subtypes can be found in Africa, where they are 
thought to have originated (Thomson et al., 2002b). Other continents have a variety of 
subtypes circulating, resulting in an uneven representation of the subtypes. Based on the 
amino acid sequence of the env region, each subtype is separated by approximately 25-30% 
genetic distance (Robertson et al., 1999; Thomson et al., 2002b). Subtypes A and F can be 
further broken down into subsubtypes, A1-A4 and F1 and F2 (Vidal et al., 2006). Technically 
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subtypes B and D are closely related and could be classified together as sub-subtypes, however 
they are generally still mentioned separately for consistency (Lal et al., 2005). In addition, 
within subtypes there are clusters that represent strains from different geographical locations, 
such as subtype B strains from Thailand, which are referred to as B’ or Thai B (Kalish et al., 
1995). These clusters most likely arose due to the initial introduction of only a small number of 
strains into a particular region, and their subsequent diversification and spread (known as a 
founder effect) (Thomson et al., 2002b). In addition to the nine subtypes of HIV-1, there exists 
circulating recombinant forms (CRFs), which are mosaic viruses of two or more HIV-1 
subtypes. To be classified as a CRF, an inter-subtype recombinant virus must be isolated from 
at least two (preferably three) unlinked individuals and sequenced in full (Carr et al., 1998). 
Currently 34 CRFs have been recognized, with 26 described in detail (Los Alamos HIV 
Database) (Figure 6). These CRFs now include second generation CRFs such as CRF09_cpx 
and CRF15_01B, which is contain the primary CRFs CRF02_AG and CRF01_AE respectively. 
Regions within CRFs that cannot be classified as a known subtype are designated U for 
unknown, and a CRF comprised of more than two subtypes is denoted by cpx for complex 
(Peeters, 2000; Robertson et al., 1999). The first CRF identified was CRF01_AE, and was 
originally classified as subtype E, before it was designated a recombinant (CRF01_AE has 
subtype A gag and pol regions and a subtype E env) (Gao et al., 1996), and interestingly a full-
length subtype E virus has not been identified, possibly indicating that the gag and pol regions 
were lost through an ancestral recombination event (Gao et al., 1996). 
Recombination is common in HIV and it uses recombination in order to acquire viral fitness, 
virulence and ability to evade the host immune system. Recombination occurs as a result of the 
low affinity binding of RT, which is necessary for the strand transfers of reverse transcription 
to occur. As HIV carries two copies of its viral RNA, during reverse transcription both of these 
can serve as templates to generate the provirus. If the two copies of RNA encapsulated with a 
virion are distinct, and are both used during reverse transcription, then the resulting provirus 
will be a recombinant. Thus the first requirement for recombination is a dually infected cell, 
which can give rise to a heterozygous virion, which carries two distinct copies of RNA. Once a 
heterozygous virion is formed recombination then occurs upon infection of a new cell (Figure 
3). The theories behind how recombination occurs at the molecular level can be divided into 
two groups, recombination that occurs during the synthesis of the minus-strand DNA and that 
which occurs during the synthesis of the plus-strand DNA. Each theory has its own 
explanation and some supporting experimental evidence, implying that both mechanisms can 
occur (Hu and Temin, 1990b). 
3. Heterozygous virions and their formation 
A requirement for the generation of recombinant HIV genomes is a heterozygous virion, 
that is, a virion with two non-identical RNA strands (Hu and Temin, 1990a; Weiss et al., 
1973). Heterozygous virions are generated in individual cells which are infected with two or 
more different viral variants, which integrate their proviral genome, and generate new full 
length viral RNA. 
As packaging of the viral RNA is not selective for specific RNA copies (D'Souza and 
Summers, 2005), a heterozygous virus can be formed, by encapsidation of an RNA copy 
from each viral variant. Heterozygous virions can then infect other cells and recombination 
between the two co-packaged viral RNAs can occur during reverse transcription (Duesberg, 
1968). (Figure 3). The different viral RNAs can come from variants within the viral 
quasispecies, or from other HIV strains or subtypes, if the patient has a dual infection. 
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Multiple infection of a single cell with HIV can occur simultaneously or sequentially. There is 
some debate regarding the sequential infection, as once a cell is infected, HIV downregulates 
the CD4 and CCR5 receptor molecules (Michel et al., 2005), and therefore simultaneous 
infection may be the primary mechanism involved. Interestingly, a study by Dang et al. (2004) 
showed that dual infections of cells occurs at a much higher rate than predicted by chance, in 
both a T cell line, and primary T cells, regardless of how the virus was transmitted. In a follow 
up study it was also shown that coreceptor differences were not a barrier to recombination, as 
viruses using different co-receptors, CCR5 or CXCR4 also exhibited rates of double infection 
that were higher than predicted from a random distribution (Chen et al., 2005). Likewise, other 
studies have also shown co-infection of cells to be common, which implies that opportunities 
for recombination are favoured (Jung et al., 2002). 
 
 
Fig. 3. HIV dual infection of a cell, heterozygous virion formation and recombination. 
Modified from: Najera et al. (2002). 
3.1 Minus-strand recombination 
There have been several studies addressing minus-strand recombination, and it has been 
shown to occur frequently, with an average of three crossovers occurring per replication 
cycle (Yu et al., 1998). 
The first mechanism proposed to account for recombination was the forced copy-choice 
model (Coffin, 1979), and was based on evidence that suggested the genomic RNA of 
retroviruses is fragmented. A break in the RNA would halt reverse transcription and 
consequently force the reverse transcriptase to switch to the second copy of RNA in order to 
continue synthesis, that is, a strand transfer event would occur (Hu and Temin, 1990b). In 
order for this to take place, the RT enzyme must be transferred to a homologous region on 
the second RNA copy. This model assumes therefore that recombination occurs during 
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minus-strand synthesis, and is comparable to the minus-strand strong stop strand transfer 
that occurs during reverse transcription (Negroni and Buc, 2001) (Figure 4). However, no 
studies have been able to establish a firm connection between strand switching and the 
frequency of RNA breaks. Further, experiments have shown that a strand break is not 
necessary for a template switch (Hu and Temin, 1990b). Consequently, the minus-strand 
exchange model was proposed which suggests that the low processivity (loose adherence to 
the RNA template) of RT causes strand transfers (Coffin, 1979; Yu et al., 1998). It has also 
been shown that obstacles to reverse transcription, causing the enzyme to pause, can trigger 
a strand transfer (Wu et al., 1995). In addition, studies have also suggested that secondary 
structures of the RNA templates could also increase template switching without a pause, by 
bringing the two templates into close proximity (Balakrishnan et al., 2001) (Figure 4). 
3.2 Plus-strand recombination 
Recombination that occurs during the synthesis of the positive strand of DNA is referred to 
as the strand displacement assimilation model (Hu and Temin, 1990b). This model suggests 
that both copies of viral RNA are transcribed to produce two minus-strand DNA copies. 
Synthesis of plus-strand DNA is initially discontinuous, and internally initiated fragments 
occur eg. at the cPPT (Hsu and Taylor, 1982). Therefore, it has been proposed that an 
internally initiated fragment can be displaced by an elongating upstream DNA fragment, 
and this can cause the internally initiated fragment to dissociate and re-anneal to the 
complementary region of the second minus-strand DNA. The resulting double stranded 
DNA will have a mismatched region and mismatch DNA repair will then correct the 
sequence differences (Hu and Temin, 1990b) (Figure 4). Two positive strands of RNA, which 
may contain breaks. During minus-strand synthesis, the RT can switch to the other template 
at a break. 
 
 
Fig. 4. Model of retrovirus recombination: minus-strand recombination (forced-copy choice) 
and plus-strand recombination (strand displacement assimilation). 
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4. The global distribution of HIV-1 subtypes and CRFs 
Across the globe there is an uneven representation of the HIV-1 M group subtypes (Figure 2), 
along with the presence of diverse subtypes and its CRFs in Asia (Figure 5). This uneven 
distribution is thought to have arisen partially due to a founder effect, where one subtype is 
introduced into a region by a single or a few individuals from which the epidemic radiates out 
(Korber et al., 2000). Subtype A is currently divided in to four sub-subtypes: A1-A4. Subsubtype 
A1 is one of the more common variants and is found throughout Western, Central and Eastern 
Africa and Eastern Europe, and two CRF forms containing subtype A1 (CRF02_AG and 
CRF03_AB) are also widely spread in these regions (Andersson et al., 1999; Bobkov et al., 2004; 
Dowling et al., 2002; Steain et al., 2005). Subtype A (sub-subtypes 1 and 2) strains are highly 
predominant in Kenya, with one study showing 93% of all strains found in the region being 
subtype A or a recombinant containing subtype A (Dowling et al., 2002). In addition, CRF01_AE 
is one of the major strains found in Thailand and Southeast Asia (McCutchan et al., 1992; 
Tovanabutra et al., 2004). Subsubtype A2 was first identified from sequences originating in the 
Democratic Republic of Congo and Cyprus (Gao et al., 2001), and is now also found in Kenya 
(Visawapoka et al., 2006). In addition, there have been 2 recognised CRF forms, CRF16_A2D 
and CRF21_A2D, both of which were also identified in Kenya (Visawapoka et al., 2006). 
CRF16_A2D has also achieved a global spread and has been identified in Korea and Argentina 
(Gomez-Carrillo et al., 2004). Subsubtype A3 has only been recently described (Meloni et al., 
2004a), and has thus far only been identified in areas of West and Central Africa (Meloni et al., 
2004a; Meloni et al., 2004b). Similarly subsubtype A4 is a relatively new strain, and has only 
been identified within the Democratic Republic of Congo (Vidal et al., 2006). 
Subtype B is the most common subtype in Australia, as well as the USA, and Western and 
Central Europe (de Oliveira et al., 2000; Essex, 1999; Herring et al., 2003). It is also found in 
South America, where CFR012_BF also circulates (Montano et al., 2005), Thailand (B’ 
strains), with CRF15_01B (Tovanabutra et al., 2001), China, with CRF07_BC and CRF08_BC 
(Saksena et al., 2005), Spain with CRF14_BG (Delgado et al., 2002) and Eastern Europe with 
CRF03_AB (Liitsola et al., 1998). This subtype was one of the first to spread globally, 
however generally seems to be on the decline, with the wider spread of other subtypes and 
intersubtype recombinants (Soares et al., 2005; Tatt et al., 2004). 
Subtype C is currently the most prevalent subtype. It is found circulating widely through 
South Africa, East Africa and India (Bessong et al., 2005) and to a lesser extent in South 
America, Eastern Europe and Chine (Saksena et al., 2005; Soares et al., 2005). It has been 
suggested that strains of subtype C possess some selective advantage due to its rapid 
dispersal across the globe that has been seen in recent years (Walker et al., 2005). 
Subtype D is found across most of Africa, particularly East African countries, where in 
Uganda it has been reported as a predominating strain (Harris et al., 2002). It has also been 
reported in other continents, though usually as a minor variant (Tatt et al., 2004). In 
addition, subtype D is frequently a component of unique intersubtype recombinants, from 
Kenya and other East African countries (Steain et al., 2005), and it has been suggested that 
recombinants between subtypes A and D are selected for in dually infected patients (Songok 
et al., 2004). Subsubtype F1 is found in South America and Europe, whereas subtype F 
strains from Africa (eg Cameroon) more commonly belong to subsubtype F2 (Laukkanen et 
al., 2000). Subtype F also forms part of CRF12_BF, which has become widespread across 
South America, and more recently as a part of CRF17_BF, CRF28_BF and CRF29_BF, which 
have also been identified in South America (De Sa Filho et al., 2006; Hierholzer et al., 2002). 
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CRF05_DF has also been reported in Europe, although is thought to have arisen in Africa 
(Casado et al., 2003; Laukkanen et al., 2000). 
 
 
Fig. 5. The complex HIV-1 genetic diversity and the spread of the predominant HIV-1 
strains in Asia. Distribution of different HIV-1 subtypes and CRFs (demonstrated in 
descending order; from the most to the least prevalent strain) in major Asian countries, 
including subtypes A; B; C; D; G, CRFs such as 01_AE, CRF01_AE; 02_AG, CRF02_AG; 
07_BC, CRF07_BC; 08_BC, CRF08_BC; 33_01B, CRF33_01B and other HIV-1 recombinant 
forms: BC, B/C inter-subtype recombinant; 01B, CRF01_AE/B; 01C, CRF01_AE/C and 
01BC, CRF01_AE/B/C. The three different routes of spread for subtype C, CRF01_AE as 
well as subtype B, C and B/C recombinants are highlighted in green, red and blue, 
respectively. Diagram source: Lau et al. (2007). 
Subtype G has been reported across Africa, and parts of Europe (Esteves et al., 2003; Gutierrez 
et al., 2004; Parreira et al., 2005; Yang et al., 2005a), however it is its CRF02_AG that has had the 
greater impact. This strain is currently the most prevalent CRF and is found predominantly 
across West and Central Africa (Mamadou et al., 2003). CRF14_BG, as well as other G 
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recombinants are also found in Spain and neighbouring regions (Perez-Alvarez et al., 2003). 
Subtypes H, J and K have had only a minor impact on the HIV epidemic and are generally 
only found in small numbers across West and Central Africa (Mokili et al., 1999; Thomson et 
al., 2002b; Vidal et al., 2000; Yang et al., 2005a). The remaining CRFs are also found in varying 
proportions, usually each within a distinct geographical region. Whole spectrum of emerging 
and well-established CRFs have been identified, which are listed in Figure 6. 
5. Dual infections and recombination of HIV 
The magnitude of genetic diversity in a host relates to the size of the viral population, the 
extent of replication, the mutation and recombination rates and the selective pressures 
placed on the virus (Saksena et al., 2001). Overall the divergence between the circulating 
HIV strains within a single individual and the original infecting strain/s is thought to 
increase by around 1% per year in early infection (Shankarappa et al., 1999). Thus, within an 
individual a heterogeneous viral population exists which has been termed a ‘quasispecies’. 
Within an individual this viral diversity can reach as 15% (Lukashov and Goudsmit, 1997). 
The reasons behind such viral diversity include a fast turnover of virions, approximately 109 
new virions are produced each day (Ho et al., 1995), and the low fidelity of reverse 
transcriptase. Reverse transcriptase lacks a proof-reading function, meaning that any 
nucleotides that are mis-incorporated during DNA synthesis are not corrected (Battula and 
Loeb, 1976). Studies have shown the mutation rate of HIV RT to be 3.4 x 10-5 mutations per 
base pair per cycle, which is relatively high compared to other retroviruses (Mansky and 
Temin, 1995). However, as the rate of recombination, 3-9 crossovers per round of replication 
(Jetzt et al., 2000), exceeds the mutation rate, recombination is the largest contributing factor 
in viral evolution (Bocharov et al., 2005). 
Intra-strain recombination between variants within the viral quasispecies, as well as inter-
strain/intersubtype recombination, increases genetic diversity and thereby increases the 
chance of survival for the virus. Recombination can generate strains capable of evading the 
host’s immune system, strains that are resistant to one or more antiretroviral drugs, or that 
can replicate faster and more efficiently (Steain et al., 2004). It can also result in the 
formation of novel genes (Sharp et al., 1996). Recombination can also be a repair mechanism 
for HIV, allowing viral replication to continue in the presence of a break in a strand of RNA. 
However, recombination can also result in the emergence of less fit viral strains, as it can 
break-up favourable combinations of genes and therefore is not always advantageous for 
the virus (Bretscher et al., 2004). 
Studies have shown that multidrug resistant viruses emerge rapidly in the presence of two 
drugs, due to recombination between strains that were each resistant to a single drug 
(Moutouh et al., 1996). In vivo, this could allow the emergence of strains that are resistant to 
many different classes of drugs, and recently intrapatient recombination leading to a 
multidrug resistant strain has been reported (Weiser et al., 2005). Further, selective pressure 
placed on the pol region in the presence of anti-retroviral drugs, does not need to be carried 
across the entire genome as recombination could occur between strains with diverse gag 
and env regions with an escape mutant in the pol region (Charpentier et al., 2006). Similarly, 
a study of two patients by van Rij et al. (2003) observed that after the emergence of X4 
utilising strains, the R5 and X4 gp120 envelope sequences diverged from each other, 
whereas the respective gag p17 regions did not. Thus it was proposed that recombination 
was occurring between the two strains in vivo. 
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Fig. 6. Schematic representation of the genomic organization of the described CRF genomes. 
Adapted from the Los Alamos National Laboratory HIV Database (2006b). 
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Recombination may also produce virus strains that are more successfully transmitted either 
via sexual contact or perinatal transmission, possibly by increasing the strains affinity for a 
particular tissue type. A study in Buenos Aires by Thomson et al. (2002b), showed that 
recombinant viruses predominated in IDUs and heterosexually infected women, whereas 
subtype B viral strains were more common in men, both heterosexually and homosexually 
infected (Gao et al., 1996). Studies have also shown that inter-subtype recombinants were 
more likely to be transmitted via breast milk than subtype C in Tanzania (Koulinska et al., 
2006). Further, in Southeast Asia, CRF01_AE was spread much more rapidly than subtype B, 
which was also present in the area. In addition, no type E gag or pol gene has been found 
which may suggest that the recombinant CRF01_AE virus was more viable and 
consequently the pure type E was eliminated by selective pressures 
6. HIV co-infection and superinfection: Pathogenic implications  
It is widely recognised that a single individual can become infected with more than one 
HIV-1 subtype or strain i.e. they harbour a dual infection (Gottlieb et al., 2004; Wang et al., 
2000). This circumstance is possible via superinfection or coinfection. In superinfection, new 
infection takes place with a divergent HIV-1 or HIV-2 strain in already infected individuals. 
In contrast, coinfection is a concomitant exposure to diverse HIV strains prior to 
seroconversion, and therefore before the immune system has mounted a response (Steain et 
al., 2004). 
For the majority of patients that have been characterized as being infected with two or more 
HIV strains, it has generally been assumed that the infections occurred within a very short 
period of time, if not simultaneously. This is because it was originally thought that 
establishment of infection with HIV would provide some immunity against re-infection, and 
that the decrease in the expression of CD4 molecules would make superinfection unlikely 
(Benson et al., 1993). Furthermore, a study by Otten et al. (1999) examined HIV-2 infection in 
Pig-tailed Macaques and found that a secondary infection could only be established in the 
first 2-4 weeks after the initial infection. 
However, there are to date at least 10 papers examining patients with evidence of 
superinfection (Chohan et al., 2005; McCutchan et al., 2005; Smith et al., 2005). These include 
one patient with a triple infection who was thought to have acquired an additional 2 strains 
through superinfection (van der Kuyl et al., 2005). It was also initially hypothesised that if 
superinfections were occurring that they would be the result of intravenous inoculation of 
the virus, with a high dose exposure. However of the reported superinfections, several were 
acquired via sexual exposures, including heterosexual contact (Chohan et al., 2005). 
Many of these papers documenting superinfection note that upon acquisition of a second 
virus, patients tend to experience a more rapid disease progression, with an increase in 
plasma viral load and a concomitant decrease in CD4+ T cell count (Smith et al., 2005; van 
der Kuyl et al., 2005). Superinfection has also been reported to lead to recombination 
between the two infecting strains (McCutchan et al., 2005). For these reasons HIV-infected 
individuals should be warned that safe-sex practices are still necessary even between sero-
concordant couples, to prevent superinfection and the associated disease progression (Steain 
et al., 2004). 
Now that superinfection has been demonstrated, it is unknown if these are rare cases or if 
superinfection is a more common event that is not always detected, and may in part provide 
some explanation for the large number of recombinant strains seen globally. In cases where 
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the second infecting strain is of the same subtype, the differences between the strains may 
be attributed to the normal quasispecies variation seen within a patient, and therefore may 
not be recognized as superinfections. Thus in cases where superinfection is detected it is 
likely to be intersubtype related and thus any quantification of superinfections may be an 
underestimation (Steain et al., 2004). 
It is important to screen for dual infections, as such patients can provide an ideal setting for 
examining biological and molecular interactions between two viral strains in vivo. Wang et 
al. (2000), reported the case of a patient who was co-infected with two divergent forms of 
subtype B, which appeared to be acting in synergy. The two strains were able to segregate 
based on a differential tropism for monocytes and macrophages. While one of the strains 
appeared to dominate when co-cultured in peripheral blood mononuclear cells (PBMCs), it 
was discovered that this strain was only able to productively infect PBMCs when the second 
viral strains was present, indicating a potential synergistic effect between the two viral 
strains. In addition, a greater cytopathic effect was observed when the two strains where co-
cultured, further supporting the idea that a synergistic association of these two viral strains 
resulted in greater pathogenicity. The patient had acquired the infections via intravenous 
drug use and progressed rapidly to AIDS, dying within 5 years of infection. This case 
demonstrates that distinct biological differences exist between strains of the same subtype, 
and that two strains are able to act in synergy. 
7. CRFs and pathogenic implications: Asia the “hotbed” of CRFs 
The highly unequal geographic distribution of viral variants is the result of the global 
variation in the HIV-1 strains, the dynamic nature of the HIV-1 epidemic, and the accidental 
epidemiologic transmissions. The recombinant HIV-1 strains have been reported from 
almost all geographic regions of the globe where multiple HIV-1 subtypes have been 
circulating. Despite this, few HIV-1 geographic “recombination hotspots” have been 
identified around the world, such as central Myanmar [Vidal et al., 2005], Yunnan province 
of China [Saksena et al., 2005], Argentina [Renjifo et al., 2001], Brazil [Ball et al., 2003], East 
Africa [Yang et al., 2003,Renjifo et al., 2004] and more recently Cuba [Wu et al., 2001]. While 
the predominant viral forms in the global HIV epidemic are subtypes A and C 
[UNAIDS/WHO, 2006], a different and even more complex HIV genetic diversity has been 
found in Asia. The HIV spread and its epidemiology in Asia are interesting and closely 
related to the routes of spread of the epidemic. This is evident from the distribution of 
subtype C  (Figure 5), which was found primarily in India and Africa, and is now spreading 
to Northern India, Myanmar, and Thailand [Eshleman et al., 2005]. Although the biological 
aspects that explain this high rate of infection remain unclear, subtype C has dominated the 
HIV-1 epidemic in India and accounts for almost 97% of infections. Apart from the 
predominant subtype C, the A/C and B/C inter-subtype recombinants have also been 
recently identified in North-eastern India [Peeters et al., 2000]. Emergence of A/C 
recombinants is also consistent with the epidemic observed in Bangladesh [Sanders-Nuell et 
al., 2007], from where triple recombinants between subtypes A, C and G have been recently 
reported. Also, it is established that the spread of subtypes B and C, as well as B/C 
recombinants occurred through the drug route from Eastern Myanmar into Yunnan 
province of China and moving to north and west into Xinjiang province of China (Figure 5).  
While other recombinants account for only 4% of the total HIV-1 infection in South and 
Southeast Asia, the CRF01_AE has been found to be responsible for 84% of all HIV-1 
www.intechopen.com
 
HIV Recombination and Pathogenesis – Biological and Epidemiological Implications 
 
109 
infections. CRF01_AE, which was originally identified in Thailand appears to circulate in 
major parts of Asia, particularly Southeast Asia (Figure 5 and 6). Together, CRF01_AE and 
other recombinants account for nearly 89%, the highest across the world [Hemelaar et al., 
2006]. Since the beginning of HIV pandemic in the last two decades until recently, changes 
in HIV-1 subtype distribution in Asia have been overwhelming. In Asian countries, the HIV-
1 prevalence has been high from the late 1980s to 1990s, with subtype B” (known as the Thai 
variant of subtype B) being the predominant strain and was most frequently observed 
amongst IDU [Weniger et al., 1991; Nerurkar et al., 1997]. Concurrently in Thailand and 
other areas, CRF01_AE was introduced independently in commercial sex workers [Ou et al., 
1993]. Interestingly in the last decade, a gradual yet evident spread of the Thai variant of 
CRF01_AE was witnessed in many countries of Asia [Nerurkar et al., 1996]. It was later 
observed that CRF01_AE takes over in the HIV-1 epidemic in Southeast Asia, even among 
IDUs in Thailand, Cambodia, and Vietnam [Nerurkar et al., 1996]. Likewise, countries such 
as Indonesia and Malaysia demonstrate the predominance of CRF01_AE and subtype B 
prior to the year 2000. 
8. Inter-CRF recombination and its possible epidemiologic implications  
Among all the HIV-1 subtypes distributed in Asia, CRF01_AE is reported to play a 
considerably important role in its epidemic [Hemelaar et al., 2006]. The HIV epidemiology 
in Asia is bound to be more complex as other recombinant forms are introduced from 
neighbouring geographic regions, along with the continuing emergence of novel second and 
third generation recombinant forms of CRF01_AE in this region. Geographic regions known 
as recombination hotspots in Asia, including Myanmar and Yunnan province of China 
appear to have varied and complex forms of HIV-1 recombinants, which emerge 
continually. Between 2002 and 2004, a novel inter-CRF recombinant has been identified in 
Yangon, Myanmar, which also appears to be a second class of HIV-1 inter-CRF 
recombinants comprised of CRF01_AE and CRF07_BC [Takebe et al., 2006]. Other Asian 
region, for instance Macao has first identified the circulation of CRF12_BF (prevalent in 
Brazil) among the IDUs, although CRF01_AE has always being the major HIV-1 strain 
[Chan et al., 2007a]. This suggests the epidemiologically associated transmission of the 
current HIV-1 infection in the region and gives clues to the possible initiation of the 
emergence of novel inter-CRF recombinants between CRF01_AE and CRF12_BF. 
Concurrently in Macao, a diverse form of HIV-1 recombinant has been recently full-length 
characterized and comprised of CRF12_BF, CRF14_BG and subtype G [Chan et al., 2007b].  
As the result of the co-circulation of subtypes B and C, two CRFs; CRF07_BC and CRF08_BC 
have emerged in the Yunnan province of China [Piyasirisilp et al., 2000]. An ongoing 
evolution and emergence of novel recombinant forms of HIV are anticipated in this region, 
while these two CRFs continue to co-circulate with “pure” subtypes B and C, along with 
other URF in Yunnan [Yang et al., 2002]. It is predicted that more new recombinant strains 
between these two CRFs will continue to emerge [Peeters et al., 2000]. With the extensive 
variability in recombinant breakpoints and crossover points in China, a possible emergence 
of second and third generation recombinant CRF will continue to give rise to more HIV-1 
variants. A recent study has identified approximately 12% of HIV-1 strains found among the 
IDUs in Southeast Yunnan to be the diverse forms of inter-CRF recombinants between 
CRF07_BC and CRF08_BC [Chan et al., 2007]. This further provides a good insight into 
inter-CRF recombinants, and only time will tell regarding epidemiologic. 
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9. HIV fitness in vivo and in vitro as a consequence of recombination 
Fitness is a parameter defining the replicative adaptation of an organism to its environment 
[Domingo et al., 1997] as a consequence of the interaction of a multitude of viral and host 
factors [Quinones-Mateu et al., 2006; Nijhuis et al., 1999 ]. Within a given viral 
„quasispecies”, each clone possesses a fitness denoting to the selection of the viral properties 
(e.g. activity and stability) in a particular environment. Under a certain selective pressure in 
a defined microenvironment, viral replication will take place to encode virus that replicates 
at high rates [331]. Thus, one or more strains possessing better viral properties within a 
given quasispecies will be positively selected, while unfit variants will be negatively 
eliminated [331]. The HIV-1 viral factors that affect viral fitness are mainly the biological 
processes in the virus life cycle: cell entry, genome replication, protein synthesis and 
processing, and particle assembly and release from cells. The survival of the fittest form of 
HIV-1 recombinant leads to further viral evolution in a complex population, suggesting a 
continuous evolving of HIV-1 dynamics, mainly attributed to an incessant process of 
growth, competition and selection.  
As a result of high mutation rate of HIV-1, wide range of sequence possibilities is created. 
While sometimes it resulted in non-replicative viruses, others may possess varying degree of 
fitness. Recombinant viruses may have some advantages over the parental strain and thus, 
may possess important genetic variability for HIV-1 pathogenesis, transmission, diagnosis, 
treatment and vaccine development. It is undeniable that different biological properties of 
diverse subtypes will possibly result in transmissibility and pathogenicity variation. During 
early infection, most subtypes conform to the non-syncytium-inducing CCR5 receptor usage 
phenotype. However, towards the late infection, these subtypes will shift to the syncytium-
inducing CXCR4 receptor usage phenotype. This is true for most but subtype C and D 
viruses, which do not follow this pattern [336]. In terms of transmission, several studies of 
vertical transmission have suggested that the maternal HIV-1 subtype is likely to play a role 
while others disregard this perception [Yang et al., 2003; Tapia et al., 2003].  
What is yet to be known is the consistent role of the subtype-associated differences in the 
efficiency of transmission via different routes. While some studies have reported that subtype 
D is associated with faster disease progression compared with subtype A [Condra et al., 1995], 
others have denied the possibilities that HIV genetic subtype determines the rate of disease 
progression [Alaeus et al., 1999]. Findings of these studies are inconsistent, due to the 
difference in the study design (sample size, duration of clinical follow-up and the use of 
surrogate markers of progression) as well as other virus, host and environmental factors. 
Previous work has also suggested possible biological differences among the HIV-1 subtypes 
[Jeeninga et al., 2000]. It was reported that the long terminal repeat (LTR) region of CRF01_AE 
(the predominant HIV-1 strain in Asia) is much more potent in vitro than the subtype B LTR. 
When a recombinant CRF01_AE/B virus was constructed in vitro, it exhibited an intense 
replication advantage compared to the parental subtype B. This indicated that restrained 
differences in the LTR promoter activity can exert a significant impact on viral replication 
kinetics. A recent profound analysis was done by Kozaczynska et al. [Kozaczynska et al., 2007] 
to describe the study over time of HIV-1 isolates in a patient twice superinfected with HIV-1; 
an initial infection with a subtype B1 strain, followed by first superinfection with a subtype B2 
strain and then with CRF01_AE. Again, the LTR of CRF01_AE was found to possess a higher 
promoter activity, although this was not reflected in the plasma viral load differences. It is 
remarkable that the later-arriving viruses (strain B2 and CRF01_AE) replicated at much higher 
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levels in blood compared with the first infecting virus B1. Except for the excessive 
recombination between both subtype B strains, there was only minimal evidence that the 
different HIV-1 strains found in the patient appeared to influence the evolution of each other. 
While HIV-1 has been constantly exposed to host immune system for eradication of the virus, 
its replication relies profoundly on host cell machinery. Thus, the HIV-1 fitness is said to be 
closely related to the host environment (e.g. cellular receptors, intracellular factors and host 
defence mechanism). Viral diversity gives important impact in the determination of viral load, 
as well as viral diagnosis. Therefore, HIV-1 diagnosis test, which includes HIV-1 
immunoassays have to be competent in detecting all known group M subtypes [Koch et al., ]. 
Other viral load measurements assays have to be reliable too, for instance polymerase chain 
reaction-based assays for quantification of the HIV-1 RNA from all known genetic variants of 
HIV-1 [Swanson et al., 2005].  
Genotypic or phenotypic variations within different subtypes are somehow related to any 
differences in ex vivo fitness. Troyer et a.l [Troyer et al., 2005] provided evidence that 
increased viral fitness in vivo may be related to a concomitant increase in HIV-1 diversity, 
and thus serves as a crucial factor in determining disease progression. Furthermore, HIV-1 
strains that display viral properties that increase their fitness, for instance subtype C isolates 
appear to have an extra or third nuclear factor-kappa B (NFκB) element in the long-terminal 
repeat (LTR). This would enhance transcription in the presence or absence of HIV-1 Tat 
protein [Hunt et al., 2006]. Another study showed that in comparison to subtype B, subtype 
C possesses an increased protease activity, and thus augmented cleavage of peptide 
substrates and possibly improved viral fitness [Velazquez et al., 2001]. Therefore, it is 
proposed that the increased replicative capacity of subtype C over other HIV-1 subtype 
isolates suggests its dominance in HIV-1 epidemic. However, in another pair-wise 
competition study by Arien et al. [Arien et al., 2005] to establish the „pathogenic fitness” (or 
virulence) of HIV in PBMCs, subtype C seems to have lower fitness when competed with 
other HIV-1 group M (subtypes A, B, D and CRF01_AE). These viruses were classified as 
using either CCR5 or the CXCR4 co-receptor for entry and were competed against the same 
phenotype to determine the fitness (based on > 2000 competitions). In the same study, it was 
reported that all HIV-1 group M viruses have a greater fitness than HIV-2 and HIV-1 group 
O showed the lowest fitness. Thus, with the exception of subtype C, this fitness order seems 
to reflect the prevalence of HIV in the human population and also the proposed rates of 
transmission efficiency. It has been reported in 2003 that the CCR5 HIV-1 subtype C isolates 
were at least 100-fold less fit than any other group M HIV-1 isolates [Ball et al., 2003]. 
Throughout the disease, subtype C isolates was predicted as preferentially CCR5-tropic and 
non-syncytium-inducing (NSI). This has absolute difference in infections with isolates of 
other HIV-1 subtypes, whereby the viruses switch from CCR5 to CXCR4 co-receptor entry 
during later stage of the disease. Other ex vivo [Ball et al., 2003] and in vivo study [Walker et 
al., 2005] has implied that subtype C is efficiently transmitted but is less virulent in 
comparison with other HIV-1 group M isolates. However, among all HIV strains, HIV-1 
group M seems to be more virulent and transmissible. It is believed that its progenitor might 
have been „fitter” for human infection and more adaptive, even after going through the 
rapid evolution and passage. By contrast, HIV-2 and HIV-1 groups O and N might have 
limited expansion in the human population, possibly due to poor host adaptation and 
transmission efficiencies, although the exact reasons for their poor transmissibility and 
active establishment in human populations have remained unclear and speculative.  
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Viral fitness is generally defined as the ability of the virus to replicate within the host and is 
therefore dependant on host and viral factors [Weber et al., 2003]. Recombination is thought 
to increase viral fitness. In an HIV-1 recombinant-related fitness study by Njai et al. [Njai et 
al., 2006], CRF02_AG isolates demonstrated a higher ex vivo replicative fitness compared to 
subtypes A and G from the same geographic region in Cameroon, irrespective of the level of 
CD4+ count and co-receptor tropism. A similar study by Konings et al. [Vijay et al., 2008] 
showed a 1.4 to 1.9 times higher replication rate increase in the CRF02_AG strains, in 
contrast to its progenitor subtypes A and G; an adaptation which implies its broader spread 
and predominance in West Central Africa. A computer simulation has been developed that 
mimic the HIV genomic diversification within an infected individual and elucidate the 
influence of recombination [Vijay et al., 2008]. This study has shown that recombination 
increases viral fitness regardless of the size of the effective population. In light of these 
results, it is likely that HIV-1 recombination events in Asia can also contribute to the 
emergence of viruses for instance, the widespread CRF01_AE/B inter-subtype recombinants 
with a biological edge in their host. In vitro studies of the viral fitness and interactions 
between different viral strains have been assessed with limitation, as only viral replication 
capacity, defined as “intrinsic capacity of virus to replicate in an ideal environment” [Weber 
et al., 2003] can be studied in the absence of host selection pressures. As a result, viral 
replication capacities are compared in vitro between two or more HIV-1 strains in dual 
infection cultures. This can be achieved by establishing a competition assay, whereby 
primary strains or recombinant viruses are competed against laboratory strains or parental 
isolates. In general, two HIV-1 strains are allowed to replicate concurrently for a designated 
period of time, or as an alternative, HIV-1 recombinant viruses, which are unable to produce 
new infectious virions are used in a single cycle growth assay, to limit the replication to a 
single cycle. The experiment is analysed through the measurement of the proportion of each 
of the initial strains to give a relative replication capacity at the end of the assay. Few studies 
have taken this approach in order to compare a number of different HIV-1 strains including 
drug resistance mutants [Weber et al., 2003,Van Maarseveen et al., 2006], isolates from HIV-
progressors versus LTNPs [Arien et al., 2005], variable subtypes, as well as different HIV-1 
groups or HIV-1 versus HIV-2. To date, none of these studies have been performed on the 
currently emerging CRF01_AE/B inter-subtype recombinants from Malaysia, particularly 
CRF33_01B. It is therefore important and urgent to identify and understand the biological 
advantages of these new HIV-1 forms, which presumably will take over the predominance 
in HIV-1 epidemic in Malaysia. 
10. Anti-HIV therapy, drug resistance and its dissemination: An example of 
China 
In global terms, over the past 15 years the treatment of HIV-1 infection has evolved 
significantly.  In North America and Western Europe, no effective therapy existed until the 
development and availability of zidovudine (ZDV, AZT) in 1987.  In 2005, there are now 26 
commercially available antiviral agents (both RT inhibitors [NRTI and NNRTI] and protease 
inhibitors) to treat HIV-1-infected individuals.   
ARV treatment of HIV-1-infected patients in China fell behind that of most developed 
countries. While highly active antiretroviral therapy (HAART) became widely used in North 
America and Western Europe in 1996, China was still debating whether or not HIV/AIDS 
would become a huge epidemic there, despite the large number of IDUs testing positive in 
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the southwest province of Yunnan and almost all provinces reporting HIV cases. In 1998, 
facing the rapid upsurge in HIV-1 incidence nation-wide, the Chinese government made a 
concerted effort to strategize the “Middle and Long-term Programming for the Prevention 
and Control of AIDS” in China.  A year later in 1999, several small clinical trails were 
initiated in Beijing primarily for safety and efficacy testing, sponsored largely by 
international pharmaceutical companies. The drug regimen tested then consisted of 
Combivir plus either Indinavir or Abacavir. This small-scale trial period (1999-2001) can be 
regarded as the first phase of ARV treatment in China.       
The second treatment phase started when the cost of imported drugs used for HAART 
declined significantly and more patients could afford the medications (2001-2003).  The 
population of Chinese patients undergoing therapy for HIV increased, especially in 
economically developed areas such as Beijing and Shanghai.  However, the number of 
clinical doctors trained to administer these drugs did not expand.  Many patients did not 
have the opportunity to receive comprehensive care, including standardized immunologic 
and virologic assessments prior to treatment and regularly scheduled follow-up interviews. 
Some patients judged the efficacy of the medication by a moderation of their symptoms, and 
consequently decreased their dosage or stopped taking the medicine altogether, without the 
consent of a physician. Of the patients who initiated treatment in this period, an estimated 
25-30 % stopped taking medicine after only one or two months.  Whether or not the other 
patients were able to persist with treatment and return for follow-up interviews is still to be 
determined.  
The third phase of treatment (2003-present) began with the availability of low-priced 
domestically manufactured and imported generic anti-HIV drugs. This has been undeniably 
the most beneficial phase in increasing the number of individuals receiving gratis treatment. 
Nation-wide free ARV treatment started in 2003, part of the China CARES program, 
consisting of 51 model sites with plans to further expand to 127 counties. However, the 
bigger hurdle for this ambitious plan has been again the critical shortage of properly trained 
doctors, nurses and community care workers. Some patients were so anxious to begin taking 
medicine for HIV that they obtained the necessary drugs without a doctor’s prescription. As 
a consequence, lacking professional guidance and clinical supervision, they used the 
medicines improperly, leading to the development of a drug resistant virus. In addition, as 
generic HIV drugs entered the Chinese market from developing countries, some patients 
began taking medicine without any medical assessment before treatment, and without 
choosing to register for interviews during treatment. Furthermore, severe side effects 
associated with generic ARV produced in China led to a large number of patients stopping 
medication entirely or becoming unwilling to follow doctors’ advice and suggestions.  As 
the incidence of HIV infection rises in China, it is anticipated that problems associated with 
the abuse of ARV will only escalate. It is therefore expected that drug resistant HIV-1 strains 
will emerge leading to their high prevalence and transmission over time.   
A number of studies in other countries have shown that the prevalence of viruses with drug 
resistance mutations in acutely or recently infected persons varies between 10 to 20% [Boden 
et al., 1999; Grant et al., 2002; Little et al., 2002]. Research examining the prevalence and 
genetic features of drug-resistance strains at national level is lacking in China. Several major 
institutes in China are combining forces to carry-out genetic studies on viruses collected 
before and after nation-wide free ARV treatment.  Based on preliminary data, it is fairly 
clear that the prevalence of drug-resistant strains were extremely rare before year 2000. 
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Between year 2001 and 2003, however, drug-resistant strains began to emerge and in some 
areas the prevalence is as high as 5%. Beginning in 2004, there was a significant increase in 
the prevalence of drug-resistant drugs across entire China, coinciding with the nation-wide 
free ARV treatment. Some areas have reported 20-30% drug-resistant strains specifically 
against NNRTI (unpublished data), and some areas were reported to have as high as 60% 
drug-resistant strains. The significant increase in the prevalence of drug-resistance could be 
due to the selection of the cohort and the time from transmission to resistance testing. 
However, it has clearly shown that resistance tests should be recommended routinely for 
patients with new infection.  
The widespread use of antiretroviral drugs has led to the development and subsequent 
transmission of drug-resistant HIV-1 and the transmission of drug-resistant viruses has been 
documented through vertical, sexual, and parenteral routes [Erice et al., 1993; Masquelier et 
al., 1993; Veenestra et al., 1995]. Patients who are infected with drug-resistant HIV-1 and 
initiate antiretroviral therapy show poorer treatment responses than patients who are 
infected with wild-type (WT) viruses [Grant et al., 2002; Little et al., 2002]. Also, in the 
absence of selection pressures exerted by drugs, some transmitted drug-resistance 
mutations may persist for months before reversion to a more replication-competent variant. 
Even when these drug resistant mutations are no longer detectable by population-based 
nucleotide-sequence, they can persist in the reservoir of latently infected CD4+ memory T 
cells and may rapidly reemerge under the selective pressure provided by antiretroviral 
treatment [Wong et al., 1997; Finzi et al., 1997]. In subjects who acquired drug-resistant virus 
during primary infection, plasma HIV RNA is not suppressed as readily by potent 
antiretroviral therapy. The slower response to the treatment and the limited viral 
suppression may facilitate the selection of variants with greater drug resistance. 
Thus, given the current spread and changing trends in HIV epidemiology in China, it is 
extremely urgent to understand the prevalence of drug-resistant strains in China and its 
changing patterns over time. Otherwise, we will face insurmountable challenges in tailoring 
our ARV regimens to elicit optimal therapeutic responses. In addition, the recombination 
between drug resistance HIV-1 strains in the Asia-pacific can cause epidemiologic shift, 
which may eventually compromise effective drug treatments currently available in these 
countries, including China. Since, at present, China and India are the economic hubs of Asia 
the human trafficking may lead to effective dispersal of such recombinant viruses. 
Therefore, well-coordinated international approaches are needed for surveillance and 
monitoring of the emergence of new drug resistance recombinant viruses. 
11. Conclusions 
It is hard to predict how the future of HIV epidemic will shape-up, since a number of 
complicating factors appear to unfold, including the possible effects of government 
intervention and unexpected changes (for the better or for the worse) in the behavior of 
affected populations. However, it is likely that the number of HIV infections is now on the 
rise, it is expected that the total number of HIV infections in China and India will surpass 
rest of the world, if no effective countermeasures are taken. Nonetheless, recombination 
between HIV-1 strains in geographical areas where multiple subtypes circulate will continue 
to shape future HIV epidemic through the generation of fitter strains capable of transmitting 
and dispersing in human populations fatser. China, India and other developing countries 
provide the right medium for this scenario. These countries stand at a critical juncture to 
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prevent widespread of HIV transmission from the high-risk groups to the general 
population. Comprehensive approaches are necessary, integrating prevention and treatment 
efforts. Government, NGO, and international organizations bear responsibility to stop this 
epidemic in China. Scientific communities and pharmaceutical companies both inside and 
outside China need to work jointly to develop more potent anti-HIV drugs and therapeutics 
to inhibit viral replication and reduce HIV transmission. We have seen clear evidence in 
favor of evolution of complex second and third generation recombinant viruses. Continued 
monitoring and surveillance of these viruses is needed, if an HIV vaccine is to be developed. 
Moreover, concerted efforts by joint ventures between the state and the private sector are 
highly needed for developing an HIV vaccine for the ultimate control of HIV and its spread 
in the most populous nation of the world. 
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